For many Gen Z girls and teenagers scrolling through TikTok, Instagram, and YouTube, advertisements for GLP-1 medications have become nearly impossible to avoid. Videos promising dramatic transformations, influencer testimonials celebrating rapid weight loss, and telehealth promotions offering easier access to prescriptions have helped turn drugs like Wegovy and Ozempic into household names. But as these medications gain visibility among younger audiences, health experts say the conversation often leaves out critical information about who these drugs are designed for and the risks they carry.

GLP-1 receptor agonists were initially developed to help manage type 2 diabetes by regulating blood sugar levels. Some medications in this class, including Wegovy, later received approval from the U.S. Food and Drug Administration for chronic weight management in adults and adolescents ages 12 and older who meet specific criteria for obesity. The drugs work by mimicking hormones that regulate appetite, helping people feel full for longer periods of time.

Yet while the science behind these medications is rooted in treating chronic disease, their growing presence on social media has reframed them as lifestyle products for many young women navigating intense pressure around body image.

For teenagers who medically qualify for treatment, GLP-1 medications may offer meaningful health benefits when prescribed as part of a comprehensive treatment plan. However, Novo Nordisk, the manufacturer of Wegovy, reports that the most common side effects seen in adolescent clinical trials included nausea, vomiting, diarrhea, constipation, abdominal pain, headaches, and fatigue. According to the company’s prescribing information, gastrointestinal symptoms were among the most frequently reported adverse events among teens using the medication.

The FDA has also warned of more serious complications associated with GLP-1 medications. Federal regulators note that patients may face an increased risk of pancreatitis, gallbladder disease, including gallstones, kidney problems related to dehydration, and severe gastrointestinal complications that require medical attention. The agency advises patients to seek immediate medical care if they experience persistent or severe abdominal pain.

Beyond physical side effects, experts are increasingly examining how these medications intersect with adolescent mental health and eating behaviors. The National Eating Disorders Association has cautioned that GLP-1 drugs may present unique concerns for individuals with active eating disorders, a history of disordered eating, or those vulnerable to developing unhealthy relationships with food. In guidance published on its website, NEDA notes that appetite suppression and rapid weight loss can be particularly concerning in a society where thinness is often equated with success, especially among young people who are still developing their identities and self-image.

Those concerns may resonate strongly with Gen Z girls, who have grown up in an era of constant digital comparison. Research published in recent years has consistently linked social media exposure to increased body dissatisfaction among adolescent girls and young women. For teens of color, these pressures can be compounded by longstanding health inequities, cultural expectations, and barriers to accessing high-quality healthcare.

Black and Latina adolescents, for example, experience disproportionate rates of obesity-related health conditions while often facing obstacles to specialty care and evidence-based treatment. Public health experts argue that discussions about GLP-1 medications in these communities must acknowledge the broader context of healthcare access, affordability, medical mistrust, and the lack of culturally responsive care that many families encounter.

The rise of online weight-loss services has also raised safety concerns. In a public alert, the FDA warned consumers about compounded versions of semaglutide after receiving reports of dosing errors that resulted in serious adverse events, including hospitalizations. Some patients mistakenly administered doses significantly higher than prescribed, leading to severe nausea, vomiting, dehydration, and other complications requiring medical intervention.

At the same time, use of these medications among adolescents appears to be increasing. Reuters recently reported that prescriptions for Wegovy among U.S. teenagers rose sharply over the past year, reflecting both growing awareness and expanding acceptance of medical treatment for obesity. The trend has prompted researchers to call for continued study of the long-term effects of GLP-1 use in younger populations, particularly because adolescents are still undergoing critical physical and emotional development.

Questions surrounding mental health risks have also drawn national attention. Earlier this year, the FDA announced that its review of available evidence did not identify an increased risk of suicidal thoughts or behaviors linked to GLP-1 medications. The agency subsequently requested the removal of warnings related to suicidal ideation from certain product labels. However, the FDA emphasized that patients, parents, and healthcare providers should remain attentive to any unusual changes in mood or behavior and report concerns promptly.

For Gen Z women and teenagers whose feeds are saturated with messages promising transformation through weight loss, the growing popularity of GLP-1 medications presents a complicated reality. These drugs can be effective treatment options for some patients under appropriate medical supervision. But health experts caution that they are not beauty shortcuts or social media trends to be pursued without careful consideration. As advertisements continue to reach younger audiences, ensuring that teens and their families receive accurate information from trusted medical sources may be just as important as understanding what these medications can do.